Proton Pump Inhibitors
11
3
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
9%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
Deprescribing Inappropriate Proton Pump Inhibitors
Intestinal Microbiota After PPI Treatment
RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention
Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program
Efficacy of a Multi-faceted Intervention to Deprescribe Proton Pump Inhibitors (PPI) in Primary Care: a Population-based, Pragmatic, Cluster-randomized Controlled Trial.
Efficacy of a Multi-faceted Intervention Combining an Educational Outreach Visit to General Practitioners and Patient Education Material to Deprescribe Proton Pump Inhibitors (PPI): a Population-based, Pragmatic, Cluster-randomized Controlled Trial
Should I Continue Taking My Acid Reflux Medication? Development and Pilot Testing of a Patient Decision Aid
Cohort Study of Clopidogrel and Proton Pump Inhibitors
Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium
High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment